L3VLUP
ProSign in

ASND in the 13F filings

Ascendis Pharma A · CUSIPs 04351P101, K08588103

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
30 Sep 2023
the date the book describes
Filed
5 Nov 2026
latest of these filings; the earliest 8 Nov 2023
Managers listing it
8
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q2 2023 and Q3 2023; 8 listed it in both
Shares listed
21,339,146
combined, among listed positions
Reported value
$2.0bn
combined, at the quarter end

Managers listing ASND in Q3 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

8 of 8 holders

ActionFiling
Artisan Partners LP5,995,408$561m0.95%Trimmed-227,0439 Nov 2023 (the filing on sec.gov)
Fidelity (FMR LLC)5,136,282$481munder 0.1%Trimmed-4,5235 Nov 2026 (the filing on sec.gov)
Janus Henderson Group Ltd3,854,533$361m0.24%Trimmed-26,82914 Nov 2023 (the filing on sec.gov)
Wellington Management Group LLP3,277,172$307m0.06%Added+128,27214 Nov 2023 (the filing on sec.gov)
T. Rowe Price Associates Inc1,637,848$153munder 0.1%Trimmed-419,31614 Nov 2023 (the filing on sec.gov)
MFS Investment Management1,264,470$118munder 0.1%Added+176,9488 Nov 2023 (the filing on sec.gov)
Verition Fund Management LLC87,112$8.2m0.10%Trimmed-22,94614 Nov 2023 (the filing on sec.gov)
Baillie Gifford & Co86,321$8.1munder 0.1%Trimmed-4,18113 Nov 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2023 to Q3 2023, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
15 in Q3 2024 to 12 in Q2 2026

Tracked managers listing it, at least.

05101520201820192020202120222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
ASND by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20171$2.1mn.a.n.a.
Q3 20172$4.7mn.a.n.a.
Q4 20171$4.8mn.a.n.a.
Q1 20186$362mn.a.n.a.
Q2 20184$310mn.a.n.a.
Q3 20183$359mn.a.n.a.
Q4 20184$638mn.a.n.a.
Q1 20198$1.7bnn.a.n.a.
Q2 20198$1.9bnn.a.n.a.
Q3 20198$1.7bnn.a.n.a.
Q4 201912$2.8bnn.a.n.a.
Q1 20209$2.3bnn.a.n.a.
Q2 20208$3.2bnn.a.n.a.
Q3 20209$4.1bnn.a.n.a.
Q4 202012$4.5bnn.a.n.a.
Q1 202110$3.4bnn.a.n.a.
Q2 202110$3.4bnn.a.n.a.
Q3 202110$4.5bnn.a.n.a.
Q4 202111$3.7bnn.a.n.a.
Q1 202210$3.3bnn.a.n.a.
Q2 20229$2.5bnn.a.n.a.
Q3 202212$2.7bnn.a.n.a.
Q4 202212$3.0bnn.a.n.a.
Q1 20239$2.6bnn.a.n.a.
Q2 20238$1.9bnn.a.n.a.
Q3 20238$2.0bnn.a.n.a.
Q4 202311$2.8bn57
Q1 202416$3.4bn106
Q2 202414$2.8bn87
Q3 202415$3.1bn115
Q4 202411$2.6bn67
Q1 202513$3.2bn76
Q2 202511$3.2bn56
Q3 202515$3.7bn68
Q4 202514$3.7bn1614
Q1 202610$3.1bn725
Q2 202612$4.3bn199

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

ASND and LLY →ASND and JNJ →ASND and VRTX →Choose a stock to compare with ASND →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own ASND, latest filings →Back to the 13F Explorer →